Advances in the Orthopedic Management of Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) can be a debilitating disease with a wide range of phenotypic manifestations. The Sillence subtypes of OI can be explained by different variations in genetic mutations. Bisphosphonate therapy augments bone turnover and increases bone density in OI patients, although its efficacy in preventing fracture, reducing pain, and improving function is controversial. Recommendations for indications, duration, and type of bisphosphonate therapy in children have not been agreed upon. Fassier-Duval rodding systems show great promise in decreasing fracture rates while requiring less revision and causing fewer complications traditionally seen with older systems.